BBIO
Price
$34.85
Change
-$0.97 (-2.71%)
Updated
May 8 closing price
Capitalization
6.62B
83 days until earnings call
PGEN
Price
$1.35
Change
-$0.00 (-0.00%)
Updated
May 8 closing price
Capitalization
398.47M
94 days until earnings call
Ad is loading...

BBIO vs PGEN

Header iconBBIO vs PGEN Comparison
Open Charts BBIO vs PGENBanner chart's image
BridgeBio Pharma
Price$34.85
Change-$0.97 (-2.71%)
Volume$5.32M
Capitalization6.62B
Precigen
Price$1.35
Change-$0.00 (-0.00%)
Volume$2.41M
Capitalization398.47M
BBIO vs PGEN Comparison Chart
Loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. PGEN commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and PGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (BBIO: $34.85 vs. PGEN: $1.35)
Brand notoriety: BBIO and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 172% vs. PGEN: 178%
Market capitalization -- BBIO: $6.62B vs. PGEN: $398.47M
BBIO [@Biotechnology] is valued at $6.62B. PGEN’s [@Biotechnology] market capitalization is $398.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, BBIO is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 5 TA indicator(s) are bullish while PGEN’s TA Score has 4 bullish TA indicator(s).

  • BBIO’s TA Score: 5 bullish, 5 bearish.
  • PGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than PGEN.

Price Growth

BBIO (@Biotechnology) experienced а -9.24% price change this week, while PGEN (@Biotechnology) price change was -12.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

BBIO is expected to report earnings on Jul 31, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($6.62B) has a higher market cap than PGEN($398M). BBIO YTD gains are higher at: 27.004 vs. PGEN (20.536). PGEN has higher annual earnings (EBITDA): -136.11M vs. BBIO (-436.83M). BBIO has more cash in the bank: 681M vs. PGEN (28.6M). PGEN has less debt than BBIO: PGEN (5.75M) vs BBIO (1.73B). BBIO has higher revenues than PGEN: BBIO (222M) vs PGEN (3.96M).
BBIOPGENBBIO / PGEN
Capitalization6.62B398M1,663%
EBITDA-436.83M-136.11M321%
Gain YTD27.00420.536131%
P/E RatioN/AN/A-
Revenue222M3.96M5,602%
Total Cash681M28.6M2,381%
Total Debt1.73B5.75M30,110%
FUNDAMENTALS RATINGS
BBIO vs PGEN: Fundamental Ratings
BBIO
PGEN
OUTLOOK RATING
1..100
1665
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
73
Overvalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4050
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (4) in the null industry is significantly better than the same rating for PGEN (73). This means that BBIO’s stock grew significantly faster than PGEN’s over the last 12 months.

BBIO's Profit vs Risk Rating (88) in the null industry is in the same range as PGEN (100). This means that BBIO’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's SMR Rating (96) in the null industry is in the same range as BBIO (97). This means that PGEN’s stock grew similarly to BBIO’s over the last 12 months.

BBIO's Price Growth Rating (40) in the null industry is in the same range as PGEN (50). This means that BBIO’s stock grew similarly to PGEN’s over the last 12 months.

BBIO's P/E Growth Rating (100) in the null industry is in the same range as PGEN (100). This means that BBIO’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOPGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
78%
Bullish Trend 16 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BLOK43.321.91
+4.61%
Amplify Transformational Data Shrg ETF
DTEC45.710.79
+1.76%
ALPS Disruptive Technologies ETF
MFM5.21N/A
N/A
MFS Municipal Income Trust
DIEM27.61-0.05
-0.17%
Franklin Emerging Mkt Core Div TltIdxETF
VWOB63.35-0.23
-0.36%
Vanguard Emerging Mkts Govt Bd ETF

BBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with ARGX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BBIO
1D Price
Change %
BBIO100%
-2.71%
ARGX - BBIO
46%
Loosely correlated
-8.64%
AXON - BBIO
44%
Loosely correlated
+14.13%
ARRY - BBIO
43%
Loosely correlated
+9.13%
PMN - BBIO
43%
Loosely correlated
-10.63%
ROIV - BBIO
41%
Loosely correlated
-1.25%
More